Page 109 - Read Online

Mauri et al. Mini-invasive Surg 2022;6:49 https://dx.doi.org/10.20517/2574-1225.2022.34 Page 11 of 13

CONCLUSION
The optimal antithrombotic therapy after TAVR is still a matter of debate. However, based on current
evidence, a single antiplatelet therapy can be considered the first-line treatment in patients not requiring
long-term OAC and without recent coronary stent implantation. Conversely, VKA or DOAC alone should
be continued without antiplatelet therapy after the procedure when there is an indication for OAC.

DECLARATIONS
Authors’ contributions
Made a substantial contribution to present paper: Mauri S, Lanzillo G, Ferlini M

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS guidelines for the management
of valvular heart disease. Eur Heart J 2022;43:561-632. DOI PubMed
2. Yadgir S, Johnson CO, Aboyans V, et al; Global Burden of Disease Study 2017 Nonrheumatic Valve Disease Collaborators. Global,
regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017. Circulation 2020;141:1670-
80. DOI PubMed
3. Mangieri A, Montalto C, Poletti E, et al. Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review
topic of the week. J Am Coll Cardiol 2019;74:2088-101. DOI PubMed
4. Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve
implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous
Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021;42:2265-9.
DOI PubMed
5. Otto CM, Nishimura RA, Bonow RO, et al; Writing Committee Members. 2020 ACC/AHA guideline for the management of patients
with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical
practice guidelines. J Am Coll Cardiol 2021;77:e25-e197. DOI PubMed
6. Mastoris I, Schoos MM, Dangas GD, Mehran R. Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis,
and preventive strategies. Clin Cardiol 2014;37:756-64. DOI PubMed PMC
7. Stortecky S, Windecker S. Stroke: an infrequent but devastating complication in cardiovascular interventions. Circulation
2012;126:2921-4. DOI PubMed
8. Van Mieghem NM, Schipper ME, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve
replacement. Circulation 2013;127:2194-201. DOI PubMed
9. Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease and transcatheter aortic valve replacement: JACK state-of-
the-art review. J Am Coll Cardiol 2019;74:362-72. DOI
10. Blanke P, Leipsic JA, Popma JJ, et al; Evolut Low Risk LTI Substudy Investigators. Bioprosthetic aortic valve leaflet thickening in the